Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Role of a CYP17 Promoter Polymorphism for Familial Prostate Cancer Risk in Germany

ZORICA VESOVIC, KATHLEEN HERKOMMER, WALTHER VOGEL, THOMAS PAISS and CHRISTIANE MAIER
Anticancer Research March 2005, 25 (2B) 1303-1307;
ZORICA VESOVIC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATHLEEN HERKOMMER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WALTHER VOGEL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
THOMAS PAISS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTIANE MAIER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 25 no. 2B 1303-1307
PubMed 
15865082

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received September 21, 2004
  • Revision received February 7, 2005
  • Accepted February 17, 2005
  • Published online March 1, 2005.

Copyright & Usage 
Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. ZORICA VESOVIC1,
  2. KATHLEEN HERKOMMER2,
  3. WALTHER VOGEL1,
  4. THOMAS PAISS2 and
  5. CHRISTIANE MAIER1
  1. 1Abteilung Humangenetik, Universitätsklinikum Ulm, Albert-Einstein-Allee 11, 89081 Ulm
  2. 2Urologische Universitätsklinik und Poliklinik, Abteilung für Urologie und Kinderurologie, Universitätsklinikum Ulm, Prittwitzstrasse 43, 89075 Ulm, Germany
  1. Correspondence to: PD Dr. med. Thomas Paiss, Urologische Universitätsklinik und Poliklinik, Abteilung für Urologie und Kinderurologie, Prittwitzstrasse 43, 89075 Ulm, Germany. Tel: 0049-731-500 27807, Fax: 0049-731-500 27856.

Cited By...

  • 13 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (2B)
Anticancer Research
Vol. 25, Issue 2B
1 Mar 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Role of a CYP17 Promoter Polymorphism for Familial Prostate Cancer Risk in Germany
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Role of a CYP17 Promoter Polymorphism for Familial Prostate Cancer Risk in Germany
ZORICA VESOVIC, KATHLEEN HERKOMMER, WALTHER VOGEL, THOMAS PAISS, CHRISTIANE MAIER
Anticancer Research Mar 2005, 25 (2B) 1303-1307;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Role of a CYP17 Promoter Polymorphism for Familial Prostate Cancer Risk in Germany
ZORICA VESOVIC, KATHLEEN HERKOMMER, WALTHER VOGEL, THOMAS PAISS, CHRISTIANE MAIER
Anticancer Research Mar 2005, 25 (2B) 1303-1307;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer
  • Combination of Polymorphisms From Genes Related to Estrogen Metabolism and Risk of Prostate Cancers: The Hidden Face of Estrogens
  • Cytochrome P450 17A1 and Catechol O-Methyltransferase Polymorphisms and Age at Lynch Syndrome Colon Cancer Onset in Newfoundland
  • Google Scholar

More in this TOC Section

  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
  • Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire